Merck (BATS-CHIXE:6MKD) - Stock Price, News & Analysis

6MKD Stock Overview

Merck & Co., Inc. operates as a healthcare company worldwide.

6MKD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	4/6

Rewards

Trading at 55.6% below our estimate of its fair value

Earnings are forecast to grow 24.88% per year

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

Has a high level of debt

Dividend of 2.41% is not well covered by earnings

+ 1 more risk

Merck & Co., Inc. Competitors

AstraZeneca

LSE:AZN

UK£187.9b

GSK

LSE:GSK

UK£71.8b

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

HUTCHMED (China)

AIM:HCM

UK£2.6b

Price History & Performance

Summary of all time highs, changes and price drops for Merck
Historical stock prices
Current Share Price	US$120.40
52 Week High	US$120.40
52 Week Low	US$92.80
Beta	0.40
1 Month Change	8.47%
3 Month Change	1.69%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	27.07%

Recent updates

Shareholder Returns

	6MKD	GB Pharmaceuticals	GB Market
7D	8.5%	1.2%	0.7%
1Y	n/a	5.2%	3.0%

Return vs Industry: Insufficient data to determine how 6MKD performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 6MKD performed against the UK Market.

Price Volatility

Is 6MKD's price volatile compared to industry and market?
6MKD volatility
6MKD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.1%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.4%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 6MKD has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 6MKD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1891	71,000	Rob Davis	www.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Merck & Co., Inc. Fundamentals Summary

How do Merck's earnings and revenue compare to its market cap?
6MKD fundamental statistics
Market cap	€300.10b
Earnings (TTM)	€2.14b
Revenue (TTM)	€57.03b

140.1x

P/E Ratio

5.3x

P/S Ratio

Is 6MKD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6MKD income statement (TTM)
Revenue	US$61.40b
Cost of Revenue	US$15.44b
Gross Profit	US$45.96b
Other Expenses	US$43.66b
Earnings	US$2.31b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 30, 2024

Earnings per share (EPS)	0.91
Gross Margin	74.85%
Net Profit Margin	3.76%
Debt/Equity Ratio	84.7%

How did 6MKD perform over the long term?

See historical performance and comparison

Dividends

2.4%

Current Dividend Yield

325%

Payout Ratio

6MKD Stock Overview

Rewards

Risk Analysis

Merck & Co., Inc. Competitors

LSE:AZN

UK£187.9b

LSE:GSK

UK£71.8b

LSE:HIK

UK£4.3b

AIM:HCM

UK£2.6b

Price History & Performance

Recent News & Updates

First quarter 2024 earnings released: EPS: US$1.88 (vs US$1.11 in 1Q 2023)

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Recent updates

First quarter 2024 earnings released: EPS: US$1.88 (vs US$1.11 in 1Q 2023)

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Fourth quarter dividend of US$0.77 announced

Upcoming dividend of US$0.77 per share

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Executive VP & General Counsel recently sold €3.5m worth of stock

Full year 2023 earnings released: EPS: US$0.14 (vs US$5.73 in FY 2022)

Third quarter dividend of US$0.77 announced

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Upcoming dividend of US$0.77 per share at 2.8% yield

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer